Business Wire

Ant Group Appointed by Elevandi as Advisory Committee Member

Share

Ant Group has been appointed as a member on the advisory committee of Elevandi, a company set up by the Monetary Authority of Singapore (MAS) with a mission to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy.

The advisory committee comprises senior leaders from eight organizations ranging from established financial institutions to Tech/FinTech players. Mr. Chen Leiming, Senior Vice President, who is responsible for Ant Group’s international public policy and government affairs, serves as the representative of Ant Group. Mr. Chen also oversees the legal, compliance, AML and privacy functions of Ant Group’s international businesses.

As an advisory committee member, Mr. Chen Leiming will represent Ant Group and involve in providing strategic guidance on:

  1. galvanising global conversations to shape FinTech industry agendas worldwide;
  2. identifying key structural trends and issues shaping the future of financial services; and
  3. fostering an open dialogue between policymakers and FinTech players on Fintech risks and opportunities.

Speaking on the appointment of Ant Group as an advisory committee member, Mr. Sopnendu Mohanty, Chairman of Elevandi’s Board of Directors and Chief FinTech Officer of MAS, said: “Elevandi's mission is to bring together the public and private sector to adopt technology and build the future of finance that is inclusive, impactful and sustainable. We welcome organisations that have shown passion and dedication in harnessing FinTech for the growth and development of the new digital economy to participate as advisory committee members.”

Mr. Chen Leiming, Senior Vice President, Ant Group, said: “It is a great honour to represent Ant Group and contribute to the mission of Elevandi which we share and resonate deeply. At Ant Group, we are committed to leveraging technology and knowledge to provide inclusive services to those unserved and underserved, and contribute to the society through initiatives such as Ant Forest to promote low carbon lifestyle, and 10x1000 Tech for Inclusion to bridge the global digital skills gap."

"We look forward to joining the fellow members of the advisory committee in furthering Elevandi’s efforts on cultivating a more inclusive, green, and sustainable fintech landscape for the future," Mr. Chen said.

As part of Ant Group’s participation in Elevandi, Mr. Douglas Feagin, Senior Vice President for Global Strategic Partnerships and Investments at Ant Group will attend Elevandi’s inaugural Point Zero Forum in Zurich as a speaker. Point Zero Forum is an invite-only, in-person gathering to frame new ideas in Web 3.0 and sustainable finance; develop new regulatory frameworks; and provide access to investment capital.

For more information on Elevandi and the full list of advisory committee members, please visit https://www.elevandi.io/media/company-set-up-by-mas-to-advance-fintech-announces-advisory-committee.

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

About Elevandi

Elevandi is set up by the Monetary Authority of Singapore (MAS) to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy. We work closely with governments, founders, investors, and corporate leaders to drive collaboration, education, and new sources of value at the industry and national levels. Our initiatives have convened over 300,000 people since 2016 to drive the growth of FinTech through events, closed-door roundtables, investor programmes, educational initiatives, and research. ​​

We have built a coordinated set of consequential products that drive activity at the industry, national, regional and global level, which include:

  • Singapore FinTech Festival (2-4 Nov 2022), our annual flagship event for the global FinTech community.
  • Point Zero Forum (21-23 June 2022), our invite only collaboration with the Switzerland government to convene leaders, investors and founders in Zurich.
  • Elevandi Connects (7 July 2022), our programme and initiative to bring together early stage start-ups with leading investors and corporates to maximise commercial success in forging investment deals, co-innovation opportunities, and business partnerships.
  • World FinTech Festival (July-Nov 2022), our partnerships with the public and private sectors in markets around the world.
  • Green Shoots Series, our monthly event meetup which serves as a platform for public and private sector announcements and to discuss critical issues and opportunities in FinTech and the digital economy.
  • Education initiatives, our certificates and mentoring programmes to upskill and reskill the global FinTech community in collaboration with Oxygen by APIX, academic and industry partners.
  • Elevandi Forums, ourpurpose-driven roundtables aimed at bringing the public and private sectors together to advance developments and issues within the FinTech industry.
  • Elevandi FinTech Insider Report, our reports on digital advancements for the global FinTech industry which synthesise knowledge from our activities with the public and private sectors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ant Group
Betty Bai
M: (65) 9183 9108
E: guzhuang.bb@antgroup.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye